Idiopathic Pulmonary Fibrosis Ipf Market 2027

DelveInsight's 'Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPF in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Idiopathic Pulmonary Fibrosis (IPF) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan


Study Period: 2016-2027


Idiopathic Pulmonary Fibrosis (IPF) - Disease Understanding and Treatment Algorithm

The DelveInsight Idiopathic Pulmonary Fibrosis (IPF) market report gives the thorough understanding of the Idiopathic Pulmonary Fibrosis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Idiopathic Pulmonary Fibrosis in the US, Europe, and Japan.


Idiopathic Pulmonary Fibrosis Epidemiology

The Idiopathic Pulmonary Fibrosis (IPF) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, diagnosed prevalent cases, age-specific, gender-specific cases and severity specific prevalent cases) scenario of Idiopathic Pulmonary Fibrosis (IPF) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to DelveInsight, the total number of diagnosed prevalent population of Idiopathic Pulmonary Fibrosis (IPF) was found to be 261,482, in the year 2016.


Idiopathic Pulmonary Fibrosis Drug Chapters

This segment of the Idiopathic Pulmonary Fibrosis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, the companies are using recombinant protein and monoclonal antibody type therapeutic classes of drugs which are contributing towards the market size of IPF. Detailed chapter for upcoming therapies like Thrombomodulin Alfa (Asahi Kasei Pharma Corporation), CC-90001 (Celgene Corporation), Gefapixant (Merck & Co., Inc.), GLPG1690 (Galapagos NV), LT-1001(LTT Bio-Pharma), BG-00011(Biogen ), BMS-986020(Bristol-Myers Squibb), LT-1002(Chong Kun Dang Pharmaceutical), Pamrevlumab (FibroGen, Inc.), PBI4050 (ProMetic Life Sciences), PRM 151 (Promedior Inc), TAS-115 (Taiho Pharmaceutical), VAY-736(MorphoSys; Novartis), Tipelukast (MediciNova)and TD139 (Bristol-Myers Squibb) have been covered in the report.


Idiopathic Pulmonary Fibrosis Market Outlook

The Idiopathic Pulmonary Fibrosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Idiopathic Pulmonary Fibrosis in 7MM was found to be USD 1,386.6 million in 2016.


Idiopathic Pulmonary Fibrosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Idiopathic Pulmonary Fibrosis Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies


Idiopathic Pulmonary Fibrosis Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition


Idiopathic Pulmonary Fibrosis Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers


Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Idiopathic Pulmonary Fibrosis market

• Organize sales and marketing efforts by identifying the best opportunities for Idiopathic Pulmonary Fibrosis market

• To understand the future market competition in the Idiopathic Pulmonary Fibrosis market.

1. Key Insights

2. IPF Market Overview at a Glance

2.1. Market Share (%) Distribution of IPF in 2017

2.2. Market Share (%) Distribution of IPF in 2027

3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)

3.1. Introduction

3.2. Staging of IPF

3.3. Risk Factors & Disease Causes

3.4. Symptoms

3.5. Pathogenesis

3.6. Diagnosis

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. 7 MM Prevalent Population of IPF

4.3. Country Wise-Epidemiology of IPF

4.3.1. United States

4.3.2. Prevalent cases of IPF in the United States

4.3.3. Prevalent Population of IPF by severity

4.3.4. Gender-Specific IPF Prevalence

4.3.5. Age-Specific IPF Prevalence

4.3.6. EU5

4.3.7. Prevalent Population of IPF in EU5

4.3.8. France

4.3.9. Prevalent Population of IPF

4.3.10. Prevalent Population of IPF by severity

4.3.11. Gender-Specific IPF Prevalence

4.3.12. Age-Specific IPF Prevalence

4.3.13. Germany

4.3.14. Prevalent Population of IPF

4.3.15. Prevalent Population of IPF by severity

4.3.16. Gender-Specific IPF Prevalence

4.3.17. Age-Specific IPF Prevalence

4.3.18. Italy

4.3.19. Prevalent Population of IPF

4.3.20. Prevalent Population of IPF by severity

4.3.21. Gender-Specific IPF Prevalence

4.3.22. Age-Specific IPF Prevalence

4.3.23. Spain

4.3.24. Prevalent Population of IPF

4.3.25. Prevalent Population of IPF by severity

4.3.26. Gender-Specific IPF Prevalence

4.3.27. Age-Specific IPF Prevalence

4.3.28. United Kingdom

4.3.29. Prevalent Population of IPF

4.3.30. Prevalent Population of IPF by severity

4.3.31. Gender-Specific IPF Prevalence

4.3.32. Age-Specific IPF Prevalence

4.3.33. Japan

4.3.34. Prevalent Population of IPF

4.3.35. Prevalent Population of IPF by severity

4.3.36. Gender-SPECIFIC IPF Prevalence

4.3.37. Age-Specific IPF Prevalence

5. Current Treatment Practices

5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)

6. Unmet needs

7. Marketed Products

7.1. Esbriet (Pirfenidone): InterMune Inc.

7.1.1. Product Description

7.1.2. Regulatory Milestones

7.1.3. Advantages & Disadvantages

7.1.4. Safety and Efficacy of Esbriet

7.1.5. Side effects of Esbriet

7.1.6. Product Profile

7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG

7.2.1. Product Description

7.2.2. Regulatory Milestones

7.2.3. Advantages & Disadvantages

7.2.4. Safety and Efficacy of Ofev

7.2.5. Side effects of Ofev

7.2.6. Product Profile

8. Emerging Therapies

9. Key Cross Competition

10. Phase III Drugs

10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation

10.1.1. Drug Description

10.1.2. Product Profile

10.1.3. Clinical Development

10.1.4. Clinical Trials Information

10.1.5. Safety and Efficacy

11. Phase II Drugs

11.1. CC-90001: Celgene Corporation

11.1.1. Drug Description

11.1.2. Product Profile

11.1.3. Clinical Development

11.1.4. Clinical Trials Information

11.1.5. Safety and Efficacy

11.1.6. Drug Description

11.1.7. Product Profile

11.1.8. Other Development Activities

11.1.9. Clinical Development

11.1.10. Clinical Trials Information

11.1.11. Safety and Efficacy

11.2. Gefapixant: Merck & Co., Inc.

11.2.1. Drug Description

11.2.2. Product Profile

11.2.3. Other Development Activities

11.2.4. Clinical Development

11.2.5. Clinical Trials Information

11.2.6. Safety and Efficacy

11.3. GLPG1690: Galapagos NV

11.3.1. Drug Description

11.3.2. Product Profile

11.3.3. Regulatory Milestones

11.3.4. Other Development Activities

11.3.5. Clinical Development

11.3.6. Clinical Trials Information

11.3.7. Safety and Efficacy

11.4. LT-1001: LTT Bio-Pharma

11.4.1. Drug Description

11.4.2. Product Profile

11.4.3. Other Development Activities

11.4.4. Clinical Development

11.4.5. Clinical Trials Information

11.4.6. Safety and Efficacy

11.5. BG00011: Biogen Inc.

11.5.1. Drug Description

11.5.2. Product Profile

11.5.3. Regulatory Milestones

11.5.4. Other Development Activities

11.5.5. Clinical Development

11.5.6. Clinical Trials Information

11.5.7. Safety and Efficacy

11.6. BMS-986020: Bristol-Myers Squibb

11.6.1. Drug Description

11.6.2. Product Profile

11.6.3. Regulatory Milestones

11.6.4. Other Development Activities

11.6.5. Clinical Development

11.6.6. Clinical Trials Information

11.6.7. Safety and Efficacy

11.7. LT-1002: Chong Kun Dang Pharmaceutical

11.7.1. Drug Description

11.7.2. Product Profile

11.7.3. Other Development Activities

11.8. Pamrevlumab: FibroGen

11.8.1. Drug Description

11.8.2. Product Profile

11.8.3. Regulatory Milestones

11.8.4. Other Development Activities

11.8.5. Clinical Development

11.8.6. Clinical Trials Information

11.8.7. Safety and Efficacy

11.9. PBI4050: ProMetic Life Sciences

11.9.1. Drug Description

11.9.2. Product Profile

11.9.3. Regulatory Milestones

11.9.4. Other Development Activities

11.9.5. Clinical Development

11.9.6. Clinical Trials Information

11.9.7. Safety and Efficacy

11.10. PRM 151: Promedior, Inc.

11.10.1. Drug Description

11.10.2. Product Profile

11.10.3. Regulatory Milestones

11.10.4. Other Development Activities

11.10.5. Clinical Development

11.10.6. Clinical Trials Information

11.10.7. Safety and Efficacy

11.11. Tipelukast: MediciNova

11.11.1. Drug Description

11.11.2. Product Profile

11.11.3. Regulatory Milestones

11.11.4. Other Development Activities

11.11.5. Clinical Development

11.11.6. Clinical Trials Information

11.11.7. Safety and Efficacy

11.12. TD139: Bristol-Myers Squibb

11.12.1. Drug Description

11.12.2. Product Profile

11.12.3. Other Development Activities

11.12.4. Clinical Development

11.12.5. Clinical Trials Information

11.12.6. Safety and Efficacy

11.13. VAY736: Novartis

11.13.1. Drug Description

11.13.2. Product Profile

11.13.3. Other Development Activities

11.13.4. Clinical Development

11.13.5. Clinical Trials Information

11.14. TAS-115: Taiho Pharmaceutical

11.14.1. Drug Description

11.14.2. Product Profile

11.14.3. Clinical Development

11.14.4. Clinical Trials Information

12. IPF: Market Analysis

12.1. Key Findings

12.2. Total Market Size of IPF in 7 MM

12.3. Therapy Based Market Size of IPF in 7 MM

13. Market Size of IPF by Country

13.1. United States Market Analysis

13.1.1. Market Size of IPF in the US

13.1.2. Therapy Based Market Size of IPF in the US

13.2. EU5 Market Outlook

13.3. Germany

13.3.1. Market Size of IPF in Germany

13.3.2. Therapy Based Market Size of IPF in Germany

13.4. France

13.4.1. Market Size of IPF in France

13.4.2. Therapy Based Market Size of IPF in France

13.5. Italy

13.5.1. Market Size of IPF in Italy

13.5.2. Therapy Based Market Size of IPF in Italy

13.6. United Kingdom

13.6.1. Market Size of IPF in the UK

13.6.2. Therapy Based Market Size of IPF in the UK

13.7. Spain

13.7.1. Market Size of IPF in Spain

13.7.2. Therapy Based Market Size of IPF in Spain

13.8. Japan: Market Analysis

13.8.1. Market Size of IPF in Japan

13.8.2. Therapy Based Market Size of IPF in Japan

14. Market Drivers of IPF

15. Market Barriers of IPF

16. Appendix

16.1. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Table 1 Expected 1-year probability of death in patients with Idiopathic Pulmonary Fibrosis (IPF)

Table 2 The GAP (Gender, Age and Physiology) score

Table 3 The GAP index and staging system

Table 4 7 MM, Historical & Forecasted IPF Prevalence, 2016-2027

Table 5 The United States, Historical & Forecasted IPF Prevalence, 2016-2027

Table 6 The United States, Historical & Forecasted Prevalence of IPF by severity, 2016-2027

Table 7 The United States, Gender-Specific IPF Prevalence, 2016-2027

Table 8 The United States, Age-Specific IPF Prevalence, 2016-2027

Table 9 EU5, Historical & Forecasted IPF Prevalence, 2016-2027

Table 10 France, Historical & Forecasted IPF Prevalence, 2016-2027

Table 11 France, Historical & Forecasted Prevalence of IPF by severity, 2016-2027

Table 12 France, Gender-Specific IPF Prevalence, 2016-2027

Table 13 France, Age-Specific IPF Prevalence, 2016-2027

Table 14 Germany, Historical & Forecasted IPF Prevalence, 2016-2027

Table 15 Germany, Historical & Forecasted Prevalence of IPF by severity, 2016-2027

Table 16 Germany, Gender-Specific IPF Prevalence, 2016-2027

Table 17 Germany, Age-Specific IPF Prevalence, 2016-2027

Table 18 Italy, Historical & Forecasted IPF Prevalence, 2016-2027

Table 19 Italy, Historical & Forecasted Prevalence of IPF by severity, 2016-2027

Table 20 Italy, Gender-Specific IPF Prevalence, 2016-2027

Table 21 Italy, Age-Specific IPF Prevalence, 2016-2027

Table 22 Spain, Historical & Forecasted IPF Prevalence, 2016-2027

Table 23 Spain, Historical & Forecasted Prevalence of IPF by severity, 2016-2027

Table 24 Spain, Gender-Specific IPF Prevalence, 2016-2027

Table 25 Spain, Age-Specific IPF Prevalence, 2016-2027

Table 26 The United Kingdom, Historical & Forecasted IPF Prevalence, 2016-2027

Table 27 The United Kingdom, Historical & Forecasted Prevalence of IPF by severity, 2016-2027

Table 28 The United Kingdom, Gender-Specific IPF Prevalence, 2016-2027

Table 29 The United Kingdom, Age-Specific IPF Prevalence, 2016-2027

Table 30 Japan, Historical & Forecasted IPF Prevalence, 2016-2027

Table 31 Japan, Historical & Forecasted Prevalence of IPF by severity, 2016-2027

Table 32 Japan, Gender-Specific IPF Prevalence, 2016-2027

Table 33 Japan, Age-Specific IPF Prevalence, 2016-2027

Table 34 Phase II/III Drug analysis

Table 35 ART-123, Clinical Trial Description, 2018

Table 36 CC90001, Clinical Trial Description, 2018

Table 37 KD025, Clinical Trial Description, 2018

Table 38 Gefapixant, Clinical Trial Description, 2018

Table 39 GLPG1690, Clinical Trial Description, 2018

Table 40 LT-1001, Clinical Trial Description, 2018

Table 41 BG00011, Clinical Trial Description, 2018

Table 42 BMS-986020, Clinical Trial Description, 2018

Table 43 Pamrevlumab, Clinical Trial Description, 2018

Table 44 PBI4050, Clinical Trial Description, 2018

Table 45 PRM151, Clinical Trial Description, 2018

Table 46 Tipelukast, Clinical Trial Description, 2018

Table 47 TD-139, Clinical Trial Description, 2018

Table 48 VAY736, Clinical Trial Description, 2018

Table 49 TAS-115, Clinical Trial Description, 2018

Table 50 Major Market Size of IPF in USD Million (2016-2027)

Table 51 Therapy Based Market Size of IPF in 7 MM in USD Million (2016-2027)

Table 52 Market Size of IPF in the US, USD Million (2016-2027)

Table 53 Therapy Based Market Size of IPF in the US in USD Million (2016-2027)

Table 54 Market Size of IPF in Germany, USD Million (2016-2027)

Table 55 Therapy Based Market Size of IPF in Germany in USD Million (2016-2027)

Table 56 Market Size of IPF in France, USD Million (2016-2027)

Table 57 Therapy Based Market Size of IPF in France in USD Million (2016-2027)

Table 58 Market Size of IPF in Italy, USD Million (2016-2027)

Table 59 Therapy Based Market Size of IPF in Italy in USD Million (2016-2027)

Table 60 Market Size of IPF in the UK, USD Million (2016-2027)

Table 61 Therapy Based Market Size of IPF in the UK in USD Million (2016-2027)

Table 62 Market Size of IPF in Spain, USD Million (2016-2027)

Table 63 Therapy Based Market Size of IPF in Spain in USD Million (2016-2027)

Table 64 Market Size of IPF in Japan, USD Million (2016-2027)

Table 65 Therapy Based Market Size of IPF in Japan in USD Million (2016-2027)

Figure 1: Risk factors associated with Idiopathic Pulmonary Fibrosis (IPF)

Figure 2: IPF associated clubbing of the fingertips

Figure 3: Stages of pathogenesis of IPF

Figure 4: A schematic representing the current model for the pathogenesis of IPF

Figure 5: Possible mechanisms of fibrogenesis in IPF

Figure 6: Chest radiograph of a patient with IPF showing bilateral lower lobe reticular opacities (red circles)

Figure 7: Subpleural honeycombing in IPF diagnosed patients

Figure 8: Diagnostic algorithm of Patients with suspected IPF

Figure 9: 7 MM, Historical & Forecasted IPF Prevalence, 2016-2027

Figure 10: The United States, Historical & Forecasted IPF Prevalence, 2016-2027

Figure 11: The United States, Historical & Forecasted Prevalence of IPF by severity, 2016-2027

Figure 12: The United States, Gender-Specific IPF Prevalence, 2016-2027

Figure 13: The United States, Age-Specific IPF Prevalence, 2016-2027

Figure 14: EU5, Historical & Forecasted IPF Prevalence, 2016-2027

Figure 15: France, Historical & Forecasted IPF Prevalence, 2016-2027

Figure 16: France, Historical & Forecasted Prevalence of IPF by severity, 2016-2027

Figure 17: France, Gender-Specific IPF Prevalence, 2016-2027

Figure 18: France, Age-specific IPF Prevalence, 2016-2027

Figure 19: Germany, Historical & Forecasted IPF Prevalence, 2016-2027

Figure 20: Germany, Historical & Forecasted Prevalence of IPF by severity, 2016-2027

Figure 21: Germany, Gender-Specific IPF Prevalence, 2016-2027

Figure 22: Germany, Age-Specific IPF Prevalence, 2016-2027

Figure 23: Italy, Historical & Forecasted IPF Prevalence, 2016-2027

Figure 24: Italy, Historical & Forecasted Prevalence of IPF by severity, 2016-2027

Figure 25: Italy, Gender-Specific IPF Prevalence, 2016-2027

Figure 26: Italy, Age-Specific IPF Prevalence, 2016-2027

Figure 27: Spain, Historical & Forecasted IPF Prevalence, 2016-2027

Figure 28: Spain, Historical & Forecasted Prevalence of IPF by severity, 2016-2027

Figure 29: Spain, Gender-Specific IPF Prevalence, 2016-2027

Figure 30: Spain, Age-Specific IPF Prevalence, 2016-2027

Figure 31: The United Kingdom, Historical & Forecasted IPF Prevalence, 2016-2027

Figure 32: The United Kingdom, Historical & Forecasted Prevalence of IPF by severity, 2016-2027

Figure 33: The United Kingdom, Gender-Specific IPF Prevalence, 2016-2027

Figure 34: The United Kingdom, Age-Specific IPF Prevalence, 2016-2027

Figure 35: Japan, Historical & Forecasted IPF Prevalence, 2016-2027

Figure 36: Japan, Historical & Forecasted Prevalence of IPF by severity, 2016-2027

Figure 37: Japan, Gender-Specific IPF Prevalence, 2016-2027

Figure 38: Japan, Age-Specific IPF Prevalence, 2016-2027

Figure 39: Suggested Algorithm for IPF Treatment

Figure 40: Unmet Needs of IPF

Figure 41: 7 Major Market Size of IPF in USD Million (2016-2027)

Figure 42: Therapy Based Market Size of IPF in 7 MM in USD Million (2016-2027)

Figure 43: Market Size of IPF in the US, USD Million (2016-2027)

Figure 44: Therapy Based Market Size of IPF in the US in USD Million (2016-2027)

Figure 45: Market Size of IPF in Germany, USD Million (2016-2027)

Figure 46: Therapy Based Market Size of IPF in Germany in USD Million (2016-2027)

Figure 47: Market Size of IPF in France, USD Million (2016-2027)

Figure 48: Therapy Based Market Size of IPF in France in USD Million (2016-2027)

Figure 49: Market Size of IPF in Italy, USD Million (2016-2027)

Figure 50: Therapy Based Market Size of IPF in Italy in USD Million (2016-2027)

Figure 51: Market Size of IPF in the UK, USD Million (2016-2027)

Figure 52: Therapy Based Market Size of IPF in The UK in USD Million (2016-2027)

Figure 53: Market Size of IPF in Spain, USD Million (2016-2027)

Figure 54: Therapy Based Market Size of IPF in Spain in USD Million (2016-2027)

Figure 55: Market Size of IPF in Japan, USD Million (2016-2027)

Figure 56: Therapy Based Market Size of IPF in Japan in USD Million (2016-2027)

Figure 57: Market Drivers of IPF

Figure 58: Market Barriers of IPF

  • Tags:
  • Idiopathic Pulmonary Fibrosis (IPF)...
  • Idiopathic Pulmonary Fibrosis (IPF)...
  • Idiopathic Pulmonary Fibrosis (IPF)...
  • Idiopathic Pulmonary Fibrosis (IPF)...
  • Idiopathic Pulmonary Fibrosis (IPF)...
  • Idiopathic Pulmonary Fibrosis (IPF)...
  • Idiopathic Pulmonary Fibrosis (IPF)...
  • Idiopathic Pulmonary Fibrosis (IPF)...
  • Idiopathic Pulmonary Fibrosis (IPF)...
  • Idiopathic Pulmonary Fibrosis (IPF)...
  • Idiopathic Pulmonary Fibrosis (IPF)...
  • Idiopathic Pulmonary Fibrosis (IPF)...
  • Idiopathic Pulmonary Fibrosis (IPF)...
  • Idiopathic Pulmonary Fibrosis (IPF)
  • Idiopathic Pulmonary Fibrosis (IPF)...
  • Idiopathic Pulmonary Fibrosis (IPF...

Forward to Friend

Need A Quote